Drug Repurposing for Alzheimer's: New Research Findings

With more than 55 million people living with Alzheimer's disease (AD) worldwide — a number projected to reach 139 million by 2050 — the urgency for effective treatments has never been greater. Yet despite decades of research and billions of dollars in drug development, most approved therapies only manage symptoms rather than addressing the disease's underlying mechanisms. A comprehensive 2026 review published in Ageing Research Reviews by More, Rangari, Lade, and colleagues examines a strategy that may help bridge this gap: repurposing drugs that are already approved for other conditions to target the complex biology of Alzheimer's disease.

What This Study Found

The review by More et al. (2026) synthesizes a growing body of evidence around drug repurposing as a therapeutic strategy for Alzheimer's disease. Because AD is characterized by multiple intersecting pathological processes — including amyloid-β plaque deposition, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, and oxidative stress — the researchers suggest that single-target therapies have historically struggled to deliver meaningful clinical outcomes.

The study highlights several drug categories currently being investigated through a repurposing lens:

• Antidiabetic agents: Metformin and GLP-1 receptor agonists are noted as promising candidates. Researchers suggest these compounds may target metabolic and inflammatory pathways implicated in AD progression.
• Antihypertensives: Candesartan, an angiotensin receptor blocker, is identified as a potential candidate, with the study pointing to its possible neuroprotective and anti-inflammatory properties.
• Anti-inflammatory drugs: NSAIDs and pioglitazone are discussed in the context of targeting neuroinflammation, a pathway increasingly recognized as central to AD pathology.
• Neuroprotective agents: Minocycline, an antibiotic with anti-inflammatory properties, and sildenafil, a phosphodiesterase-5 inhibitor, are highlighted as candidates with emerging evidence in AD-related research.

Importantly, the review draws particular attention to mitochondrial dysfunction as an early and potentially foundational driver of Alzheimer's disease development. The authors suggest that mitochondria-targeted therapeutics — including SS-31, Mdivi-1, MitoQ, DDQ, and SkQ1 — represent some of the most promising disease-modifying options currently under investigation. These compounds are designed to reduce oxidative stress and restore mitochondrial integrity, processes the study identifies as critical upstream events in AD pathogenesis.

The review also notes that advances in artificial intelligence, multi-omics platforms, and precision medicine are increasingly being integrated into drug repurposing strategies, potentially accelerating the identification of viable candidates and improving trial design.

Clinical Significance

The clinical significance of this research centers on a fundamental problem in Alzheimer's drug development: the remarkably low success rate of novel therapeutic trials. Existing approved treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, offer only symptomatic relief. More recently approved anti-amyloid monoclonal antibodies, while representing a mechanistic advance, have been associated with limited clinical efficacy in some patients, along with safety concerns and substantial cost barriers.

Drug repurposing offers a compelling alternative pathway. Because repurposed drugs have already undergone safety evaluation and regulatory review for their original indications, researchers suggest this approach can significantly reduce both the time and cost associated with bringing new treatments to patients. The review by More et al. (2026) emphasizes that repurposed agents targeting diverse pathological pathways — rather than a single mechanism — may better reflect the multifactorial nature of Alzheimer's disease.

The authors further propose that integrating multi-target repurposed therapy combinations with emerging technologies such as AI-driven drug discovery and precision medicine profiling may represent the most viable path toward genuinely disease-modifying outcomes. It is important to note, however, that many of the compounds discussed in this review remain in preclinical or early clinical stages, and robust human trial data will be necessary before conclusions about efficacy can be drawn.

Current Access and Compliance Context

One of the practical advantages of drug repurposing — and a point the study implicitly underscores — is that many of the agents under investigation are already accessible through licensed medical providers for their approved indications. Metformin, for example, is widely prescribed for type 2 diabetes. Candesartan is commonly used for hypertension management. Minocycline is an established antibiotic. Sildenafil has a well-characterized safety profile from its cardiovascular and urological applications.

This existing infrastructure of prescribing familiarity, supply chain availability, and patient education may reduce barriers to compliance if these agents are ultimately validated for AD-related use through clinical trials. However, it also introduces an important caution: the fact that a drug is accessible and familiar does not mean it is appropriate for off-label use in Alzheimer's disease outside of a clinical research setting. Patients and caregivers should not interpret the repurposing research landscape as an endorsement of self-directed off-label treatment.

Mitochondria-targeted compounds such as MitoQ and SkQ1 — some of which are available as research-grade or nutraceutical formulations — present a different access context. The study suggests these compounds show promise, but the authors are clear that clinical validation in AD populations is still needed.

What Patients Should Know

For individuals living with Alzheimer's disease, or for family members and caregivers navigating treatment decisions, this research offers both cautious optimism and important perspective. The study by More et al. (2026) reinforces that the scientific community is actively pursuing multiple novel strategies beyond the traditional drug pipeline — and that the complexity of Alzheimer's disease may ultimately require equally complex, multi-targeted therapeutic approaches.

Key takeaways for patients and caregivers include:

• Drug repurposing is an active and evidence-informed research strategy, not an experimental fringe approach. Several repurposed candidates have reached clinical trial phases.
• Mitochondrial health is emerging as an important early target. Researchers suggest that interventions addressing mitochondrial dysfunction may have potential as disease-modifying strategies, though human evidence is still developing.
• No repurposed drug should be used for Alzheimer's outside of medical supervision. Even well-known medications carry risks in different populations, dosing contexts, and disease states.
• Precision medicine approaches may soon allow for more individualized treatment selection, potentially matching patients to repurposed therapies based on their specific biological profiles.

Patients interested in participating in clinical trials investigating repurposed therapies for Alzheimer's disease are encouraged to speak with a qualified healthcare provider or consult resources such as ClinicalTrials.gov.

Conclusion

The 2026 review by More, Rangari, Lade, and colleagues offers a thorough and timely synthesis of drug repurposing strategies in Alzheimer's disease. The study suggests that by leveraging existing drugs with established safety profiles — and by targeting the disease's multiple overlapping pathological mechanisms, including the increasingly recognized role of mitochondrial dysfunction — researchers may be able to accelerate the development of more effective and accessible therapies for the millions of people affected by AD worldwide.

The integration of artificial intelligence and precision medicine into repurposing frameworks adds further reason for measured optimism. As this field evolves, staying informed and working closely with knowledgeable medical professionals will be essential for patients and caregivers seeking to understand their options.

If you are interested in speaking with a healthcare provider who is knowledgeable about emerging and evidence-based therapies, visit peptideassociation.org/find-a-doctor to find a qualified clinician in your area.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The information presented is based on a published scientific review and reflects the findings and interpretations of the study's authors. Readers should not make any changes to their medical treatment or begin any new therapy based on this content. Always consult a qualified and licensed healthcare provider before making any medical decisions.

---

Citation (AMA format): More PS, Rangari SW, Lade SN, et al. Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates. Ageing Res Rev. 2026;(published May 2026). doi:10.1016/j.arr.2026.103113. PMID: 41956136.